Side Effects of Upadacitinib
Upadacitinib carries significant safety concerns including serious infections (particularly herpes zoster), cardiovascular events, malignancies, and laboratory abnormalities, with a dose-dependent pattern where higher doses (30 mg) consistently show increased adverse event rates compared to 15 mg. 1
Black Box Warnings and Serious Risks
The FDA drug label contains critical black box warnings that must be understood 1:
- Serious infections including tuberculosis, bacterial, fungal, and viral infections that can spread throughout the body and cause death
- Increased risk of death in patients ≥50 years with at least one cardiovascular risk factor
- Malignancies including lymphoma and lung cancer (especially in current/past smokers)
- Major adverse cardiovascular events (MACE) including heart attack and stroke
- Venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism
Common Adverse Events by System
Infections
Herpes zoster is the most characteristic infection risk with upadacitinib, occurring more frequently than with other JAK inhibitors or biologics 2, 3. In atopic dermatitis trials, acne and folliculitis are among the most common cutaneous adverse events, with acne rates up to 17% at the 30 mg dose 2. Serious infection rates are comparable to adalimumab but increase with higher doses and in elderly patients 4.
Gastrointestinal Effects
Nausea is particularly prominent, reported in 7-20% of patients in atopic dermatitis studies, most commonly occurring in women within the first week of treatment with median resolution at 15 days 2. Abdominal pain, diarrhea, and vomiting also occur. Gastrointestinal perforation has been reported in rheumatoid arthritis patients but not yet in atopic dermatitis 2.
Hematologic Abnormalities
Laboratory monitoring reveals 5, 2:
- Leukopenia and neutropenia (more common with 30 mg dose at 4.4% vs 1.1% with 15 mg)
- Anemia (1.1% with 30 mg, none with 15 mg)
- Thrombocytopenia requiring potential dose reduction or discontinuation
Hepatic Effects
Liver enzyme elevations occur more frequently with upadacitinib, particularly at higher doses 2. If drug-induced liver injury is suspected or enzymes remain persistently elevated, interrupt treatment and consider gastroenterology referral.
Lipid Abnormalities
Increases in total cholesterol, LDL, HDL, and triglycerides have been reported 2. The clinical significance remains uncertain, but regular lipid monitoring is recommended.
Dermatologic Effects
Beyond acne, patients may develop 2:
- Folliculitis
- Skin reactions (generally mild-moderate)
- Increased photosensitivity requiring sun protection
Cardiovascular and Thromboembolic
Recent pharmacovigilance data shows 678 VTE cases reported globally, predominantly in women (68.1%), median age 63 years, with 91.2% classified as serious 6. The signal appears dose-dependent and more prominent compared to all medicines but similar to other JAK inhibitors.
Other Notable Effects
- Headache: Most common nervous system adverse event, generally mild and brief (median <1 day duration), affecting up to 10% 2
- Creatine phosphokinase elevations: 2.2% with 30 mg vs 1.1% with 15 mg 3
- Retinal detachment: Reported in clinical trials; patients should report sudden vision changes 1
Dose-Dependent Safety Profile
The 15 mg dose demonstrates a more favorable benefit-risk balance than 30 mg 7. Meta-analysis shows comparable efficacy between doses (OR=1.00, P=0.98) but the 30 mg dose carries increased adverse event risk (OR=1.42 vs 1.30 for 15 mg) 7. Specific adverse events including serious infections, herpes zoster, anemia, neutropenia, and liver enzyme elevations all occur more frequently at 30 mg 3.
Monitoring Requirements
Based on guideline recommendations 5:
- Baseline: Hepatitis B/C screening, latent TB testing, CBC with differential, comprehensive metabolic panel, lipid panel
- Follow-up: CBC and CMP at 4-8 weeks after starting, then every 3 months
- Lipids: Baseline, 4-8 weeks, then annually
- Liver enzymes: Monthly for first 3-6 months in some protocols
Special Populations and Contraindications
Absolute contraindications include 4, 1:
- Severe active infections
- Severe hepatic disease (Child-Pugh C)
- Pregnancy (teratogenic in animal studies with skeletal malformations)
Dose adjustments required for 4:
- Severe renal disease (CrCl <30 mL/min): reduce to 5 mg once daily for tofacitinib; baricitinib not recommended
- Drug interactions with CYP3A4 inhibitors (ketoconazole) or inducers (rifampicin)
Critical Clinical Pitfalls
- Do not substitute between upadacitinib formulations (tablets vs oral solution) 1
- Avoid live vaccines during treatment 1
- Screen for latent TB before initiation - mandatory 5, 4
- Counsel patients on infection symptoms requiring immediate medical attention 1
- Consider herpes zoster vaccination before starting therapy where appropriate 2
- Avoid in patients ≥65 years with cardiovascular risk factors unless no alternatives exist 4
Pregnancy and Lactation
Contraception is mandatory during treatment and for 4 weeks after the last dose 1. Upadacitinib caused skeletal malformations, cardiovascular defects, and embryolethality in animal studies at clinically relevant exposures. Breastfeeding is not recommended during treatment and for 6 days after the last dose 1.